Close
Ïã¸ÛÁùºÏ²Ê and AstraZeneca collaborate on immuno-oncology research
4 February 2021
Researchers from Ïã¸ÛÁùºÏ²Ê Division of Infection & Immunity will lead on two collaborative projects with AstraZeneca. The projects’ long-term aim is to contribute to the development of new cancer treatments.
The Business & Innovation Partnerships team and Ïã¸ÛÁùºÏ²Ê Consultants (Ïã¸ÛÁùºÏ²ÊC), part of Ïã¸ÛÁùºÏ²Ê Innovation & Enterprise, supported the development of these collaborations.
These research collaborations will investigate immune checkpoints which are key biochemical pathways that regulate our body’s immune responses. These are important in a number of conditions, including cancer and autoimmune diseases.
The two Ïã¸ÛÁùºÏ²Ê AstraZeneca projects are focused on increasing our understanding of immune checkpoint mechanisms and how we can manipulate them, with the aim of ultimately leading to new immunotherapy approaches.
Sharing expertise: Ïã¸ÛÁùºÏ²Ê uses unique preclinical models and an array of molecular and cell biology techniques to study these pathways. AstraZeneca will provide a number of novel compounds, with both sides sharing and building on their respective research expertise.
Read the full story on Ïã¸ÛÁùºÏ²Ê I&E News
Ìý
Images
Ïã¸ÛÁùºÏ²Ê Creative Media Services